In a recent meta-analysis which included individual-patient data from five randomized trials, beta-blocker therapy did not ...
Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. Although it can present with an ...
The original paper, ‘CXCR4 PET/CT Predicts Left Ventricular Recovery 8 Months After Acute Myocardial Infarction,’ can be found here: ...
A study published in BMC Nephrology explored whether serum angiotensinogen could serve as a reliable biomarker to identify ...
Background Percutaneous ventricular assist devices (pVAD) have been increasingly used to support haemodynamics during ...
Cardiogenic shock (CS) following acute myocardial infarction (AMI) remains one of cardiology’s most formidable challenges, carrying a mortality rate that stubbornly persists around 40–50% despite ...
Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced its successful participation in the ...
Empagliflozin reduces heart failure hospitalization risk in patients with acute myocardial infarction, irrespective of type 2 diabetes or chronic kidney disease status. The EMPACT-MI trial showed a 23 ...
Patients with GERD had a 27% increased risk for incident acute myocardial infarction. HealthDay News — Patients with preexisting gastroesophageal reflux disease (GERD) have an increased risk for ...
Incidence and outcomes of acute myocardial infarction (MI) not affected by daylight savings time, according to an observational study. Report showed no discernible week-to-week changes in MI patterns ...
When hemoglobin concentration is 10 g/dL, liberal red blood cell transfusion strategy is suggested. Monica B. Pagano, M.D., from the University of Washington in Seattle, and colleagues developed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback